公开(公告)号：US12115341B2

公开(公告)日：2024-10-15

申请号：US14443847

申请日：2013-11-20

申请人： AMGEN INC.

发明人： Lawrence Ring ,  Dhairya Mehta ,  Stephanie Toy ,  Ferry Tamtoro ,  Alexander Stuart Cairns ,  Scott R. Gibson

IPC分类号： A61M5/142 ,  A61K9/00 ,  A61K38/19 ,  A61K38/26 ,  A61K38/28 ,  A61M5/14 ,  A61M5/158 ,  A61M5/20 ,  A61M5/30 ,  A61M5/31 ,  A61M5/32 ,  A61M5/42 ,  A61M25/00 ,  A61M25/02 ,  C07K14/535 ,  C12N9/64

CPC分类号： A61M5/14248 ,  A61K9/0019 ,  A61K38/193 ,  A61K38/26 ,  A61K38/28 ,  A61M5/14 ,  A61M5/14216 ,  A61M5/158 ,  A61M5/20 ,  A61M5/3134 ,  A61M5/3286 ,  A61M5/3287 ,  A61M5/3291 ,  A61M5/422 ,  A61M25/0015 ,  A61M25/0068 ,  A61M25/007 ,  A61M25/02 ,  C07K14/535 ,  C12N9/6424 ,  A61M2005/1401 ,  A61M2005/1585 ,  A61M2005/3022 ,  A61M2005/3289 ,  A61M2025/0073 ,  A61M2202/0007 ,  A61K38/28 ,  A61K2300/00 ,  A61K38/26 ,  A61K2300/00 ,  A61K38/193 ,  A61K2300/00

摘要： A drug delivery device includes a blunt cannula and a reservoir. The blunt cannula has a cylindrical wall that defines an axial passage between a first end and a second end of the blunt cannula. The wall has at least a first tapered region at the first end to define an opening in fluid communication with the axial passage and adapted at the first end to resist interruption of fluid flow through the axial passage and out of the first end of the blunt cannula. The reservoir is connected to the second end of the blunt cannula.

公开(公告)号：US20240294674A1

公开(公告)日：2024-09-05

申请号：US18254495

申请日：2021-11-25

申请人： ASSEMBLY MEDICINE, LLC.

发明人： Fan Yang ,  James Jeiwen Chou ,  Liujuan Zhou ,  Yanbing Wang ,  Chan Cao ,  Changqing Run

IPC分类号： C07K19/00 ,  A61K47/54 ,  C07K14/535 ,  G16B15/10

CPC分类号： C07K19/00 ,  A61K47/549 ,  C07K14/535 ,  G16B15/10 ,  C07K2317/569

摘要： A construction method for and an application of a nucleic acid multimerization-mediated multivalent protein drug and vaccine. Specifically provided is a multimeric complex based on complementary nucleic acid backbones. The complex is a multimer formed by complexing of 3-6 monomers having complementary nucleic acid backbones, wherein each monomer is a polypeptide having a nucleic acid single strand. In the multimer, the nucleic acid single strand of each monomer and the nucleic acid single strands of the other two monomers form double strands by means of base complementation, so as to form complementary nucleic acid backbone structures. Also provided are a pharmaceutical composition containing the multimeric complex, a nucleic acid sequence library used for constructing the multimeric complex, and a method for optimizing complementary nucleic acid backbones. By means of the method, off-the-shelf short-acting protein drugs or antigens can be used to complete multivalent formation of protein drugs or antigens without the need of reconstruction of fusion proteins or chemical modification and cross-linking, thereby improving their half-life and activity, and/or immunogenicity.

公开(公告)号：US12049647B2

公开(公告)日：2024-07-30

申请号：US17164635

申请日：2021-02-01

申请人： Replimune Limited

发明人： Robert Stuart Coffin

IPC分类号： C12N7/00 ,  A61K35/763 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K14/005 ,  C07K14/535 ,  C07K16/28 ,  A61K39/00

CPC分类号： C12N7/00 ,  A61K35/763 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K14/005 ,  C07K14/535 ,  C07K16/2818 ,  A61K2039/505 ,  C12N2710/16621 ,  C12N2710/16622 ,  C12N2710/16632 ,  C12N2710/16633 ,  C12N2710/16643 ,  C12N2740/13022

摘要： The present invention relates to oncolytic virus comprising: (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene.

公开(公告)号：US20240182545A1

公开(公告)日：2024-06-06

申请号：US18372917

申请日：2023-09-26

申请人： UBI Pharma Inc. (UBIP)

发明人： Chang-Yi Wang ,  Wen-Jiun Peng ,  Wei-Ting Kao

IPC分类号： C07K14/745 ,  C07K14/505 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  C07K19/00

CPC分类号： C07K14/745 ,  C07K14/505 ,  C07K14/535 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  C07K19/00 ,  C12N9/644

摘要： A fusion protein is disclosed. The fusion protein of the invention comprises an Fc fragment of an immunoglobulin G and a bioactive molecule, wherein the Fc is a single chain Fc. The amino acids in the hinge of the Fc is mutated, substituted, or deleted so that the hinge of Fc cannot form disulfide bonds. Methods for producing and using the fusion protein of the invention are also provided.

公开(公告)号：US20240182535A1

公开(公告)日：2024-06-06

申请号：US18033252

申请日：2021-10-25

申请人： Partner Therapeutics, Inc.

发明人： Michael FELDHAUS ,  Jeffrey YOST

IPC分类号： C07K14/535 ,  A61K35/16 ,  A61K38/19

CPC分类号： C07K14/535 ,  A61K35/16 ,  A61K38/193

摘要： The present invention is based on the discovery that amino acid substitutions in the sequence of sargramostim yield a product with simplified manufacturability.

公开(公告)号：US20240180974A1

公开(公告)日：2024-06-06

申请号：US18326637

申请日：2023-05-31

申请人： Synlogic Operating Company, Inc.

发明人： Dean Falb ,  Jonathan W. Kotula ,  Vincent M. Isabella ,  Paul F. Miller ,  Suman Machinani ,  Saurabh Saha ,  Adam B. Fisher ,  Yves Millet ,  Ning Li

IPC分类号： A61K35/74 ,  A61K31/00 ,  A61K38/19 ,  A61K38/20 ,  A61K39/395 ,  A61K48/00 ,  A61P35/00 ,  C07K14/245 ,  C07K14/335 ,  C07K14/34 ,  C07K14/535 ,  C07K14/54 ,  C07K14/55 ,  C07K16/28 ,  C12N5/00 ,  C12N15/00 ,  C12N15/70 ,  C12P13/22 ,  C12P21/02

CPC分类号： A61K35/74 ,  A61K31/00 ,  A61K38/193 ,  A61K38/20 ,  A61K39/39541 ,  A61K39/3955 ,  A61K48/00 ,  A61P35/00 ,  C07K14/245 ,  C07K14/335 ,  C07K14/34 ,  C07K14/535 ,  C07K14/54 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/55 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C12N5/00 ,  C12N15/00 ,  C12N15/70 ,  C12P13/227 ,  C12P21/02 ,  A61K2039/505 ,  C07K2317/622 ,  C07K2319/036

摘要： Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.

公开(公告)号：US20240150792A1

公开(公告)日：2024-05-09

申请号：US18547139

申请日：2022-02-24

申请人： NorthShore University HealthSystem

发明人： Prem Seth

IPC分类号： C12N15/86 ,  A61K35/761 ,  A61K45/06 ,  A61P35/00 ,  C07K14/535 ,  C07K14/71

CPC分类号： C12N15/86 ,  A61K35/761 ,  A61K45/06 ,  A61P35/00 ,  C07K14/535 ,  C07K14/71 ,  C07K2319/30 ,  C12N2710/10032 ,  C12N2710/10041 ,  C12N2810/6018 ,  C12N2820/007

摘要： The present disclosure provides an oncolytic virus comprising a nucleic acid(s) encoding a granulocyte-macrophage colony-stimulating factor (GM-CSF) and a soluble form of the TGF-B receptor-II (sTGF-BRII). The present disclosure also provides compositions comprising the oncolytic virus and treatment methods using the oncolytic virus. The treatment methods include local and/or systemic administration of the oncolytic virus for treating cancers, such as solid tumors.

公开(公告)号：US20240123071A1

公开(公告)日：2024-04-18

申请号：US17621687

申请日：2020-05-22

申请人： Guangzhou Anjie Biomedical Technology CO., LTD.

发明人： Chao Zhou ,  Hong An ,  Youde Lu ,  Ling Zhou ,  Yongbiao Du ,  Jiaqi Tu ,  Haibin Michael Yin

IPC分类号： A61K39/00 ,  C07K14/535 ,  C12N5/0783 ,  C12N9/16 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90

CPC分类号： A61K39/464493 ,  A61K39/001193 ,  A61K39/4636 ,  C07K14/535 ,  C12N5/0638 ,  C12N9/16 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12Y301/03002 ,  A61K2039/884 ,  A61K2239/58 ,  C07K2319/02 ,  C12N2310/20 ,  C12N2501/22 ,  C12N2800/80

摘要： Provided are a preparation method for a CTL cell and an application thereof. The preparation method comprises the following steps of: inducing a CTL cell by using a tumor antigen PAP-GM-CSF sensitized DC cell; and knocking out a PD-1 gene of the CTL cell to obtain a PD-1 knock-out CTL cell. The CTL cell obtained by the preparation method can be used for preparing drugs for treatment of prostate cancer, especially for treating PAP-positive prostate cancer. The CTL cell does not cause CTL cell failure and anergy due to the tumor-expressed PD-L1 after being transfused into the body, thereby producing efficient specific cytotoxic effect on a tumor cell and improving the curative effect and reducing the side effect.

公开(公告)号：US20230416324A1

公开(公告)日：2023-12-28

申请号：US18049582

申请日：2022-10-25

申请人： Moderna TX, Inc.

发明人： Stephen G. HOGE ,  William Joseph ISSA ,  Edward John MIRACCO ,  Jennifer NELSON ,  John REYNDERS ,  Matthew STANTON

IPC分类号： C07K14/535 ,  C12P19/34 ,  C12P21/02 ,  C07K14/505 ,  C12N9/02 ,  A61K48/00

CPC分类号： C07K14/535 ,  C12P19/34 ,  C12P21/02 ,  C07K14/505 ,  C12N9/0069 ,  A61K48/005 ,  C12Y113/12007

摘要： The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.

公开(公告)号：US20230348547A1

公开(公告)日：2023-11-02

申请号：US18087045

申请日：2022-12-22

申请人： Ambrx, Inc. ,  Elanco US Inc.

发明人： Anna-Maria A. HAYS PUTNAM ,  Nick KNUDSEN ,  Thea NORMAN ,  Alan KODER ,  Vadim KRAYNOV ,  Lillian SKIDMORE ,  Peter C. CANNING

IPC分类号： C07K14/535

CPC分类号： C07K14/535 ,  A61K38/193

摘要： Modified bovine G-CSF polypeptides and uses thereof are provided.